Close Menu

NEW YORK (GenomeWeb) – 23andMe has received clearance from the US Food and Drug Administration to market its first health-related test, for Bloom syndrome, directly to consumers.

The test determines whether a healthy person carriers a genetic variant that could be passed on to a child. Bloom syndrome is an autosomal recessive disorder that results in short stature and a predisposition to cancer. The child must inherit two abnormal alleles in order to have symptoms of the syndrome.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Master's and doctoral students in the UK call on funding groups to extend their grants for the duration of the disruption caused by the COVID-19 outbreak, the Guardian reports.

Squid can make edits to their RNA within the cytoplasm of their axons, Science News reports.

The Chan Zuckerberg Initiative is putting $25 million toward COVID-19 treatment research, according to the Verge.

In Science this week: researchers engineer version of Cas9 that is nearly PAM-less, and more.

May
06
Sponsored by
Isoplexis

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.